Open AccessClinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma
Author(s) -
Raimonda Kubiliūtė,
Algirdas Žalimas,
Arnas Bakavičius,
Albertas Ulys,
Feliksas Jankevičius,
Sonata Jarmalaitė
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s330341
Subject(s) - clear cell renal cell carcinoma , dna methylation , methylation , medicine , renal cell carcinoma , clear cell , cancer research , pathological , oncology , cancer , clinical significance , kidney cancer , pathology , biology , gene , gene expression , biochemistry
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney tumors, accounting for the majority of deaths from genitourinary cancers. The currently used nomograms for predicting patient outcomes are based on clinical-pathological characteristics only; however, a significant number of ccRCC survivors with similar radiological and histological features still demonstrate a different clinical course of the disease. This study aimed at the identification of novel DNA methylation biomarkers for the monitoring of patients with ccRCC.